Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Hillmen, Peter; Robak, Tadeusz; Janssens, Ann; Govindbabu, K.; Grosicki, Sebastian; Mayer, Jiřı́; Panagiotidis, Panagiotis; Kimby, Eva; Schuh, Anna; E. Boyd, Thomas; Montillo, Marco; McKeown, Astrid; Carey, Jodi; Gupta, Ira; Chang, Chai‐Ni; Lisby, Steen; Offner, Fritz

doi:10.1182/blood.v122.21.528.528

Public

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Published in Blood • Nov 15, 2013

Authors:

Peter Hillmen

Tadeusz Robak

Ann Janssens

Abstract

Abstract Introduction Chemoimmunotherapy with purine analogues and the anti-CD20 antibody rituximab is the standard of care as initial therapy in younger and physically fit patients with chronic lymphocytic leukemia (CLL). However, most CLL patients are elderly and/or have comorbidities, meaning tha...

Subject

Chlorambucil

Medicine

Ofatumumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!